The human scaffolds are derived from biobanked tumours, with access to patient characteristics, tumour typing and morbidity/mortality data.

Iscaffpharma has developed a methodology to carefully de-cellularize the human scaffold, conserving the matrix around the cells.

The de-cellularized 3D scaffold is repopulated with cancer reporter cell’s. Thus allowing studies of the effect of the surrounding environment. This technology differs from existing 2D cultures where the cancer cells will have optimal growth opportunity. In Iscaffpharma’s scaffolds the pressure from the environment causes the cancer cells to adapt and start differentiation in several ways.

The technology allows discovery of new targets and lead generation. Examples of test in Iscaffpharma’s scaffolds include

– Drug resistance
– Proliferation
– Differentiation
– Stem cell features
– EMT

Iscaffpharma’s mission is to establish the scaffold technology as gold standard for cancer drug development and develop own successful treatments for aggressive cancer.

– Scaffold (environment) of tumour affects cancer aggressiveness
– New technology with human and 3D printed scaffolds available that mimic true human environment
– Increasing success rate in clinical development of cancer drugs
– Improved target and lead generation